Real-World Effectiveness and Safety of Intravenous Daratumumab in Patients with Multiple Myeloma: A Multicenter, Observational Study from Korea
In a rapidly evolving treatment landscape, this analysis provides insight into the real-world outcomes for patients with MM receiving daratumumab in Korea and reveals that real-world outcomes were improved over results demonstrated in a clinical trial setting.
Authors
- Youngil Koh (ORCID: https://orcid.org/0000-0002-4750-931X)
- Sung‐Hoon Jung (ORCID: https://orcid.org/0000-0003-3370-3987)
- Y.S. Park
- Kihyun Kım (ORCID: https://orcid.org/0000-0002-5878-8895)
- Sung‐Soo Park (ORCID: https://orcid.org/0000-0002-8826-4136)
- Soomin Yoon
- Sung‐Soo Yoon (ORCID: https://orcid.org/0000-0003-2591-7459)
- Je‐Jung Lee (ORCID: https://orcid.org/0000-0002-4635-5697)
- Sang Eun Yoon (ORCID: https://orcid.org/0000-0002-2472-8691)
- Chang‐Ki Min
Institutions
- Janssen (Belgium) (BE)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- Chonnam National University Hwasun Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Sungkyunkwan University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2024-12-24
- DOI
- https://doi.org/10.4143/crt.2024.781
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00